SCHEMBL1110146

SCHEMBL1110146

CCCCC(C(=O)O)N(c1ccc2cc(-c3nc(C)no3)ccc2c1)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 8/20 0.36
MMP9 P14780 8/20 0.36
MMP12 P39900 8/20 0.36
MMP13 P45452 7/20 0.36
MMP8 P22894 6/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
BRD4 O60885 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
NPY2R P49146 1/20 0.32
PPARG P37231 3/20 0.32
PPARD Q03181 3/20 0.32
PPARA Q07869 3/20 0.32
S1PR1 P21453 2/20 0.32
S1PR5 Q9H228 2/20 0.32
S1PR4 O95977 1/20 0.32
ACLY P53396 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110145 0.90 KDM4E (0.41) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1110342 0.89 MMP2 (0.34) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1110250 0.89 MMP12 (0.38) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1110220 0.87 NPC1 (0.42) BCHEACHEPPARGPPARDPPARA
SCHEMBL1110207 0.87 ALDH1A1 (0.45) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1321251 0.87 MMP12 (0.36) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1110337 0.87 FFAR1 (0.40) BRD4
SCHEMBL1110210 0.87 MAPK14 (0.38) TP53MAPTPPARGPPARDPPARA
SCHEMBL1110203 0.86 ACLY (0.32) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1110163 0.86 PPARG (0.41) MAPTPPARGPPARDPPARAS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 MMP2 3127/4885MMP9 3948/4885MMP12 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.